<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
<journal-title-group>
<journal-title>Translational Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">2158-3188</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30718812</article-id>
<article-id pub-id-type="pmc">6362161</article-id>
<article-id pub-id-type="publisher-id">410</article-id>
<article-id pub-id-type="doi">10.1038/s41398-019-0410-0</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Do polygenic risk and stressful life events predict pharmacological treatment response in obsessive compulsive disorder? A gene–environment interaction approach</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8491-0137</contrib-id>
<name>
<surname>Alemany-Navarro</surname>
<given-names>María</given-names>
</name>
<address>
<phone>+34 (0) 93 2607659</phone>
<email>mariaalemany92@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Costas</surname>
<given-names>Javier</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Real</surname>
<given-names>Eva</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Segalàs</surname>
<given-names>Cinto</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1468-7862</contrib-id>
<name>
<surname>Bertolín</surname>
<given-names>Sara</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Domènech</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rabionet</surname>
<given-names>Raquel</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carracedo</surname>
<given-names>Ángel</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6231-6524</contrib-id>
<name>
<surname>Menchón</surname>
<given-names>Jose M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alonso</surname>
<given-names>Pino</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<aff id="Aff1"><label>1</label>Institut d’ Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat (Barcelona), Spain </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8836 0780</institution-id><institution-id institution-id-type="GRID">grid.411129.e</institution-id><institution>OCD Clinical and Research Unit, Psychiatry Department, </institution><institution>Hospital Universitari de Bellvitge, </institution></institution-wrap>L’Hospitalet de Llobregat (Barcelona), Spain </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9403 4738</institution-id><institution-id institution-id-type="GRID">grid.420359.9</institution-id><institution>Grupo de Xenética Psiquiátrica, Instituto de Investigación Sanitaria de Santiago, </institution><institution>Complexo Hospitalario Universitario de Santiago de Compostela, Servizo Galego de Saúde, </institution></institution-wrap>Santiago de Compostela, Spain </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.473715.3</institution-id><institution>Centre for Genomic Regulation (CRG), </institution><institution>The Barcelona Institute of Science and Technology, </institution></institution-wrap>Dr. Aiguader 88, Barcelona, 08003 Spain </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2172 2676</institution-id><institution-id institution-id-type="GRID">grid.5612.0</institution-id><institution>Universitat Pompeu Fabra (UPF), </institution></institution-wrap>Barcelona, Spain </aff>
<aff id="Aff6"><label>6</label>CIBER in Epidemiology and Public Health (CIBERESP), Barcelona, Spain </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000000109410645</institution-id><institution-id institution-id-type="GRID">grid.11794.3a</institution-id><institution>Grupo de Medicina Xenómica, </institution><institution>Universidade de Santiago de Compostela, Centro Nacional de Genotipado - Instituto Carlos III, </institution></institution-wrap>Santiago de Compostela, Spain </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1791 1185</institution-id><institution-id institution-id-type="GRID">grid.452372.5</institution-id><institution>Centro de Investigación Biomédica en Red de Enfermedades Raras, </institution></institution-wrap>Santiago de Compostela, Spain </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution>CIBERSAM (Centro de Investigación en Red de Salud Mental), Instituto de Salud Carlos III, </institution></institution-wrap>Madrid, Spain </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0247</institution-id><institution-id institution-id-type="GRID">grid.5841.8</institution-id><institution>Department of Clinical Sciences, Bellvitge Campus, </institution><institution>University of Barcelona, </institution></institution-wrap>Barcelona, Spain </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>4</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>4</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>9</volume>
<elocation-id>70</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>18</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">The rate of response to pharmacological treatment in Obsessive-compulsive disorder (OCD) oscillates between 40 and 70%. Genetic and environmental factors have been associated with treatment response in OCD. This study analyzes the predictive ability of a polygenic risk score (PRS) built from OCD-risk variants, for treatment response in OCD, and the modulation role of stressful life events (SLEs) at the onset of the disorder. PRSs were calculated for a sample of 103 patients. Yale–Brown Obsessive Compulsive Scale (YBOCS) scores were obtained before and after a 12-week treatment. Regression analyses were performed to analyze the influence of the PRS and SLEs at onset on treatment response. PRS did not predict treatment response. The best predictive model for post-treatment YBOCS (post YBOCS) included basal YBOCS and age. PRS appeared as a predictor for basal and post YBOCS. SLEs at onset were not a predictor for treatment response when included in the regression model. No evidence for PRS predictive ability for treatment response was found. The best predictor for treatment response was age, agreeing with previous literature specific for SRI treatment. Suggestions are made on the possible role of neuroplasticity as a mediator on this association. PRS significantly predicted OCD severity independent on pharmacological treatment. SLE at onset modulation role was not evidenced. Further research is needed to elucidate the genetic and environmental bases of treatment response in OCD.</p>
</abstract>
<funding-group>
<award-group>
<funding-source>
<institution>Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia. Grant co-funded by the European Social Fund (ESF) “ESF, Investing in your future” (2017 FI_B 00327).</institution>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Juan Rodés contract (JR14/00038).</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par2">Obsessive-Compulsive Disorder (OCD) is a complex neuropsychiatric condition that may interfere severely in the patient’s life and lead to maladaptive behavior<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Lifetime prevalence of the disorder is 2–3%<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Treatment usually consists of medication and cognitive-behavioral therapy, as recommended in OCD clinical guidelines<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p>
<p id="Par3">Selective serotonin reuptake inhibitors (SSRIs) comprise the first-line pharmacological treatment for OCD. However, treatment response is variable, with the proportion of OCD patients that improve with pharmacological treatment oscillating between 40 and 70%, and in some cases only a partial response is obtained<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Non-responders may be treated with another SSRI<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, with antipsychotics as adjunctive treatment<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, or clomipramine either as monotherapy or as a coadjuvant<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
<p id="Par4">Several studies have examined the genetic and environmental factors associated with treatment response in OCD. Genetic variants in catecholaminergic (<italic>HTR2A, HTR1B, SLC6A4, COMT</italic>), glutamatergic (<italic>SLC1A1, GRIN2B, DLGAP2, SLITRK5, DLGAP1</italic>), and neurotrophic (<italic>BDNF</italic>) systems have been associated with response to SSRIs<sup><xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR13">13</xref></sup>. Some, but not all, of these genes have been related to increased risk of developing OCD (<italic>BDNF</italic><sup><xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref></sup>, <italic>SLC1A1</italic><sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, <italic>COMT</italic><sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, <italic>SLC6A4</italic><sup><xref ref-type="bibr" rid="CR19">19</xref></sup>). Meanwhile, pharmacokinetic studies have also associated variants of an enzyme from the cytochrome P450 family (<italic>CYP2D6</italic>) with response to SSRIs and non-selective serotonin reuptake inhibitors (SRIs)<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. Besides candidate gene association studies, a genome-wide association study (GWAS) has been carried out to study SSRI response in OCD. Although only one variant (located near the DISP1 gene) met the genome-wide significance level, other 41 presented indications of association; most of these variants played a role in the glutamatergic and serotonergic pathways<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. These results suggest that genetic factors may influence treatment response in OCD.</p>
<p id="Par5">GWAS data can also be used to generate an important index known as the polygenic risk score (PRS), a measure of an individual’s genetic risk conferred by common variants of the studied trait. Based on the results of a GWAS discovery sample, it is calculated as the sum of the number of risk alleles carried by an individual, weighted according to their effect<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>.</p>
<p id="Par6">The association between a PRS and treatment response has been analyzed in several psychiatric conditions, including affective disorders and schizophrenia<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. In the case of SSRI response, inconsistent data have been reported for affective disorders. As an example, researchers involved in the GENDEP, STAR*D, and MARS projects constructed a PRS for antidepressant response derived from a meta-analysis of GENDEP and MARS participants. This PRS accounted for up to 1.2% of response variance in the STAR*D sample<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Conversely, García González et al<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. constructed a PRS for treatment response in major depressive disorder (MDD) using pharmacogenetic samples from the GENDEP and STAR*D studies, but found no significant associations. To the best of our knowledge, PRS methodology has not been employed to study treatment response in OCD.</p>
<p id="Par7">Stressful conditions have also been observed to influence treatment response in several mental disorders. One of the most extensively studied of these is childhood abuse, which has been associated with treatment response in depression<sup><xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR31">31</xref></sup> and social anxiety disorder<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. A history of trauma has also been related to greater treatment resistance in OCD<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Conversely, Shavitt et al<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. found that OCD patients reporting trauma benefited more from SSRI treatment than those who did not. Further research has investigated the influence of gene–environment interaction (GxE) on treatment response. Thus, it has been reported that response to SSRIs in affective disorders is influenced by the interaction between non-traumatic but stressful life events (SLEs) and variants of the <italic>SLC6A4</italic><sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, <italic>BDNF</italic> and <italic>ST8SIA</italic> (a gene involved in neuroproliferation and neuroplasticity) genes<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. In addition, a gene associated with the catecholamine system (<italic>SLC6A2</italic>) has been related to treatment response in MDD, through an interaction with childhood abuse<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Finally, a GxE influence on treatment response has also been described in OCD for variants of the glutamatergic gene <italic>SLC1A1</italic> and SLEs at onset of the disorder<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. However, none of these studies has made use of a PRS.</p>
<p id="Par8">Given the above, the objective of this study was to analyze how genes influence treatment response in OCD, and how this influence may be modulated by certain environmental conditions. We hypothesized that a PRS built for OCD would predict treatment response to SRIs and that this association would be modulated by SLEs at onset of the disorder.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Subjects</title>
<p id="Par9">Our study sample comprised 103 Spanish Caucasian patients (46 females; mean age 33.23 ± 9.66) recruited from the OCD clinic at Bellvitge Hospital (Barcelona, Spain). All participants met the DSM-IV criteria for OCD diagnosis<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, with a duration of at least one year. Diagnoses were independently assigned by two psychiatrists with extensive clinical experience in OCD, each of whom interviewed the patients separately using the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCIDCV)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Patients were offered treatment at our clinic with a SRI (SSRI or clomipramine), considering their history of previous medication and preference. Maximum recommended doses were administered to the patients for a minimum period of 12 weeks. Exclusion criteria consisted of presenting psychoactive substance abuse/dependence (either current or in the past six months), psychotic disorders, intellectual disability, severe organic or neurological pathology except tic disorder, and autism spectrum disorder. Other affective and anxiety disorders were not considered criteria for exclusion if OCD was the main diagnosis.</p>
<p id="Par10">After receiving a full description of the study, patients were required to give their written informed consent. This study was performed in accordance with the Helsinki Declaration of the World Medical Association, and approved by the Ethical Committees of Bellvitge Hospital.</p>
</sec>
<sec id="Sec4">
<title>Clinical assessment</title>
<p id="Par11">Participants’ sociodemographic and clinical characteristics and medical data were collected in structured interviews during their first visit to our unit. Age at onset was defined as the moment when obsessive symptoms reached a clinically significant level. Baseline severity of the obsessive and compulsive symptoms was assessed through the clinician-administered version of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. The presence of obsessive/compulsive dimensions in the worst-ever period of the disorder was evaluated using the DY-BOCS scale<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Family psychiatric history was coded in percentages for each category, considering solely family members who had received a formal diagnosis.</p>
<sec id="Sec5">
<title>Treatment response</title>
<p id="Par12">Treatment response was assessed by means of a clinician-administered version of the Y-BOCS<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Patients were assessed twice: at baseline and after 12 weeks at maximum tolerated SRI doses, in both cases analyzing the severity of obsessive and compulsive symptoms.</p>
</sec>
<sec id="Sec6">
<title>Stressful life event assessment</title>
<p id="Par13">Life stress at onset of the disorder was analyzed using the methodology described in Real et al.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. In face-to-face interviews, patients were asked whether they could identify a SLE in the year prior to the onset of the disorder. Patients reporting a SLE at onset were assigned to the SLE-preceded OCD group, while the rest of the patients formed the non-SLE-preceded OCD group. Patient-reported SLEs at onset were contrasted with the Paykel Scale of Stressful Life Events<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> to confirm that these coincided with any of the 61 events listed on the scale.</p>
</sec>
<sec id="Sec7">
<title>Current treatment</title>
<p id="Par14">Thirty-six (35.0%) of the 103 patients received SSRIs (sertraline, fluoxetine, fluvoxamine, paroxetine, citalopram or escitalopram) as monotherapy according to their previous history of response. The remaining 67 (65.0%) were administered clomipramine as monotherapy due to a previous history of resistance to at least three SSRIs.</p>
</sec>
</sec>
<sec id="Sec8">
<title>Genotyping data</title>
<p id="Par15">All genotyping, quality control, and imputation procedures were carried out on an original sample consisting of 433 OCD patients and 484 controls, and are described elsewhere<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Genotypic data for cases and controls were obtained using the Axiom Exome array (Affymetrix, Santa Clara, CA, USA), following the manufacturer’s instructions. This panel includes 300 000 variants mainly from coding regions (85%), a type of variation that contributes disproportionately to single nucleotide polymorphism (SNP) heritability<sup><xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR46">46</xref></sup>. Variant call was performed using Affymetrix genotyping console software with the Axiom GT1 algorithm.</p>
<p id="Par16">Quality control procedures were carried out using PLINK. SNPs that did not pass the following filters were removed from the study: (i) genotyping call rate greater than 95%; (ii) non-significant departures from Hardy-Weinberg equilibrium in control sample (<italic>P</italic> &gt; 1 × 10<sup>−3</sup>); (iii) non-significant difference in call rate between cases and controls (P &gt; 1 × 10<sup>−3</sup>).</p>
</sec>
<sec id="Sec9">
<title>Composition of the polygenic risk score</title>
<p id="Par17">In order to generate a discovery sample, 131 samples that would constitute the target sample to study response to treatment, were removed from the genotyping data set. The target sample was selected considering the availability of neuroimaging data from these patients for another study currently underway. Then, an allelic association test for OCD status was carried out on the discovery sample using PLINK v1.07<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>, considering all the autosomal SNPs at MAF &gt; 5%. These SNPs were all included in the PRS model. The PRS in the target sample was calculated as the sum of every risk allele carried by an individual, weighted according to its effect size, measured as the logOR (using the score option in PLINK v1.07). Several different P <sub>threshold</sub>, from 0.01 to 1 (that is, inclusion of all the SNPs) were considered.</p>
</sec>
<sec id="Sec10">
<title>Statistical analyses</title>
<p id="Par18">Variance analyses were carried out using generalized linear models (GLM) to analyze the predictive power of the PRS for treatment response, and subsequently, the modulatory role of SLEs at onset in this relation. Basal and post-treatment Y-BOCS scores (basal Y-BOCS and post Y-BOCS) were included in the equation separately. Basal Y-BOCS was considered an independent variable, and post Y-BOCS, the dependent variable. An analysis of post Y-BOCS distribution was performed in order to select a link function for it in the GLM. The model was adjusted for sex, age, history of pharmacological resistance, age at onset, and family psychiatric history of OCD, given the observed influence of these factors on OCD phenotype and treatment response<sup><xref ref-type="bibr" rid="CR48">48</xref>–<xref ref-type="bibr" rid="CR50">50</xref></sup>. The Akaike information criterion (AIC) was compared between the different models executed in order to determine which showed the best fit to the data. Given the large differences between the variables’ scales, all of them were standardized in order to obtain interpretable results.</p>
<p id="Par19">To rule out any possible correlation between the PRS and the adjustment variables, variance analyses were carried out (t-test/ANOVA or Pearson correlation according to the qualitative or quantitative nature of the variables, respectively). Different models were used to analyze the predictive power of PRS for treatment response (Table <xref ref-type="table" rid="Tab1">1</xref>). First, only basal Y-BOCS was included as an independent variable in order to analyze a possible association between both Y-BOCS measures (<italic>Model 1</italic>, Table <xref ref-type="table" rid="Tab1">1</xref>). Then, a new analysis (<italic>Model 2</italic>, Table <xref ref-type="table" rid="Tab1">1</xref>) was performed that included the PRS as an independent variable together with basal Y-BOCS. <italic>Model 2</italic> was then readjusted for each of the eight abovementioned demographic and clinical variables (<italic>Model 3</italic>, Table <xref ref-type="table" rid="Tab1">1</xref>). Furthermore, since the PRS was built from OCD-risk variants, we thought it might also predict disorder severity<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> (in addition to disease status: <sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>). Then, further models were executed to analyze a possible association between each of the Y-BOCS measures and the PRS (<italic>Models 4</italic> and <italic>5</italic>, Table <xref ref-type="table" rid="Tab1">1</xref>). When basal Y-BOCS was a dependent variable (<italic>Model 5</italic>), its distribution was analyzed in order to select an appropriate link function in the GLM.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Models analyzing predictors for treatment response</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>
<italic>Model 1</italic>
</td><td>Post Y-BOCS ~ Basal Y-BOCS</td></tr><tr><td>
<italic>Model 2</italic>
</td><td>Post Y-BOCS ~ Basal Y-BOCS + PRS</td></tr><tr><td>
<italic>Model 3</italic>
</td><td>Post Y-BOCS ~ Basal Y-BOCS + PRS + Adjustments</td></tr><tr><td>
<italic>Model 4</italic>
</td><td>Post Y-BOCS ~ PRS</td></tr><tr><td>
<italic>Model 5</italic>
</td><td>Basal Y-BOCS ~ PRS</td></tr><tr><td>
<italic>Model 6</italic>
</td><td>Post Y-BOCS ~ Basal Y-BOCS + PRS + SLE</td></tr><tr><td>
<italic>Model 7</italic>
</td><td>Post Y-BOCS ~ Basal Y-BOCS + PRS + SLE + Adjustments</td></tr></tbody></table><table-wrap-foot><p><italic>Y-BOCS</italic> Yale–Brown obsessive-compulsive scale, <italic>PRS</italic> polygenic risk score, <italic>SLE</italic> stressful life event</p></table-wrap-foot></table-wrap></p>
<p id="Par20">With respect to SLEs at onset, the possibility of significant differences in PRS between those presenting a SLE at onset or not was ruled out by means of a t-test. Correlations between SLEs at onset and each demographic or clinical variable included in the models as independent variables (including basal Y-BOCS), were also tested using t-test analysis for continuous variables and chi square tests, for categorical variables.</p>
<p id="Par21">To explore the modulatory role of SLEs at onset in treatment response, a new model was constructed that included SLEs at onset as an independent variable together with basal Y-BOCS and the PRS (<italic>Model 6</italic>, Table <xref ref-type="table" rid="Tab1">1</xref>). All analyses were performed using R software version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).</p>
</sec>
</sec>
<sec id="Sec11" sec-type="results">
<title>Results</title>
<sec id="Sec12">
<title>Genotyping and quality control</title>
<p id="Par22">Quality control filtering yielded genotypic data from a sample of 370 cases and 443 controls. The final data set consisted of a total of 38 305 SNPs at a frequency &gt; 5% in the total sample. Further details on application of the quality control filters are given in Costas et al.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p>
</sec>
<sec id="Sec13">
<title>Comparison with previous GWAS</title>
<p id="Par23">Our results were compared with the available data from previous GWAS studies: SNPs at <italic>P</italic> &lt; 01 × 10<sup>−3</sup> in meta-analysis of Stewart et al.<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. and SNPs at <italic>P</italic> &lt; 01 × 10<sup>−4</sup> in the study of Matthiesen et al.<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. None of the 33 SNPs reported by Matthiesen et al. were presented in our samples. Forty-four SNPs present in our samples are among the 601 reported by Stewart et al. Two of them are at <italic>P</italic> &lt; 0.05 in our samples, but only one, rs6845865, showed the same direction of association.</p>
</sec>
<sec id="Sec14">
<title>Polygenic risk score</title>
<p id="Par24">A PRS was constructed for a total of 37 523 autosomal SNPs associated to OCD status in the discovery sample. One-hundred and three from the original 131 patients conformed the final target sample.</p>
</sec>
<sec id="Sec15">
<title>Treatment response</title>
<p id="Par25">Three patients out of the 103 that constituted the target sample did not complete the 12-week treatment. Then, treatment response was obtained for a final sample of 100 patients (44 females; mean age 33.42 ± 9.67) (Table <xref ref-type="table" rid="Tab2">2</xref>). The Patients’ scores on the Y-BOCS scale before and after the treatment period are shown in Table <xref ref-type="table" rid="Tab3">3</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Sodiodemographic and clinical characteristics of the sample of 100 OCD patients</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Age, Years, Mean ± SD (Range)</td><td>33.42 ± 9.67 (18–57)</td><td></td><td></td><td></td></tr><tr><td>Male/Female, <italic>n</italic> (%)</td><td>56/44 (56.0%, 44.0%)</td><td></td><td></td><td></td></tr><tr><td>Age at Onset of OCD, Mean ± SD (Range)</td><td>21.62 ± 10.03 (6–70)</td><td></td><td></td><td></td></tr><tr><td colspan="5"><italic>Baseline Y-BOCS Score, Mean</italic> <italic>±</italic> <italic>SD (Range)</italic></td></tr><tr><td>Global</td><td>26.26 ± 5.16 (11–36)</td><td></td><td></td><td></td></tr><tr><td>Obsessions</td><td>13.12 ± 3.24 (0-26)</td><td></td><td></td><td></td></tr><tr><td>Compulsions</td><td>12.98 ± 2.99 (0- 19)</td><td></td><td></td><td></td></tr><tr><td><italic>Baseline HDRS, Score, Mean</italic> <italic>±</italic> <italic>SD (Range)</italic></td><td>12.7 ± 5.05 (2–28)</td><td></td><td></td><td></td></tr><tr><td colspan="5">
<italic>Current Comorbid Diagnosis, n (%)</italic>
</td></tr><tr><td>No comorbid disorder</td><td>53 (53.0)</td><td></td><td></td><td></td></tr><tr><td>Other Anxiety Disorder</td><td>10 (10.0)</td><td></td><td></td><td></td></tr><tr><td>Mood Disorder</td><td>9 (9.0)</td><td></td><td></td><td></td></tr><tr><td>Tics</td><td>3 (3.0)</td><td></td><td></td><td></td></tr><tr><td>Eating Disorders</td><td>2 (2.0)</td><td></td><td></td><td></td></tr><tr><td>Other</td><td>23 (23.0)</td><td></td><td></td><td></td></tr><tr><td colspan="5">
<italic>Presence of Dimensions in worst-ever period n (%)</italic>
</td></tr><tr><td>Aggresive/checking</td><td>70 (70.0)</td><td></td><td></td><td></td></tr><tr><td>Symmetry/Ordering</td><td>43 (43.0)</td><td></td><td></td><td></td></tr><tr><td>Contamination/cleaning</td><td>49 (49.0)</td><td></td><td></td><td></td></tr><tr><td>Hoarding</td><td>26 (26.0)</td><td></td><td></td><td></td></tr><tr><td>Miscelaneos</td><td>32 (32.0)</td><td></td><td></td><td></td></tr><tr><td colspan="5">
<italic>History of Pharmacological Resistance n (%)</italic>
</td></tr><tr><td>1 SSRI</td><td>27 (27.0)</td><td></td><td></td><td></td></tr><tr><td>2 SSRIs</td><td>12 (12.0)</td><td></td><td></td><td></td></tr><tr><td>&gt;2 SSRIs</td><td>61 (61.0)</td><td></td><td></td><td></td></tr><tr><td>
<italic>Family Psychiatric History n (% of patients)</italic>
</td><td>1st grade</td><td>2nd grade</td><td>3rd grade</td><td>Total</td></tr><tr><td>No psychiatric diagnosis</td><td>47 (47.0)</td><td>38 (38.0)</td><td>80 (80.0)</td><td>30 (30.0)</td></tr><tr><td>OCD</td><td>2 (2.0)</td><td>11 (1.0)</td><td>1 (1.0)</td><td>10 (10.0)</td></tr><tr><td>Subclinic OCD</td><td>6 (6.0)</td><td>5 (5.0)</td><td>1 (1.0)</td><td>12 (12.0)</td></tr><tr><td>Anxiety disorder different from OCD</td><td>13 (13.0)</td><td>4 (4.0)</td><td>0 (0.0)</td><td>15 (15.0)</td></tr><tr><td>Mood disorder</td><td>14 (14.0)</td><td>28 (28.0)</td><td>1 (1.0)</td><td>28 (28.0)</td></tr><tr><td>Psychotic disorder</td><td>5 (5.0)</td><td>5 (5.0)</td><td>8 (8.0)</td><td>13 (13.0)</td></tr><tr><td>Drug abuse</td><td>8 (8.0)</td><td>2 (2.0)</td><td>3 (3.0)</td><td>10 (10.0)</td></tr><tr><td>Eating disorder</td><td>1 (1.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>1 (1.0)</td></tr><tr><td>Tics/ Guilles de la Tourette</td><td>2 (2.0)</td><td>5 (5.0)</td><td>4 (4.0)</td><td>9 (9.0)</td></tr><tr><td>Others</td><td>2 (2.0)</td><td>2 (2.0)</td><td>2 (2.0)</td><td>5 (5.0)</td></tr></tbody></table><table-wrap-foot><p><italic>OCD</italic> obsessive-compulsive disorder, <italic>Y-BOCS</italic> Yale–Brown obsessive-compulsive scale, <italic>HDRS</italic>, Hamilton depression rating scale</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Y-BOCS scores before and after 12-week treatment period</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3"><italic>Y-BOCS Score, Mean</italic> <italic>±</italic> <italic>SD (Range)</italic></th></tr><tr><th></th><th>
<italic>Basal YBOCS</italic>
</th><th>
<italic>Post YBOCS</italic>
</th></tr></thead><tbody><tr><td>
<italic>Global</italic>
</td><td>26.26 ± 5.16 (11–36)</td><td>19.18 ± 6.80 (6–36)</td></tr><tr><td>
<italic>Obsessions</italic>
</td><td>13.12 ± 3.24 (0–26)</td><td>9.49 ± 3.46 (3–18)</td></tr><tr><td>
<italic>Compulsions</italic>
</td><td>12.98 ± 2.99 (0–19)</td><td>9.57 3.60 (0–18)</td></tr></tbody></table><table-wrap-foot><p><italic>Y-BOCS</italic> Yale–Brown obsessive-compulsive scale</p></table-wrap-foot></table-wrap></p>
<p id="Par26">Regression analyses were carried out in a final sample of 100 patients, for which treatment response was obtained.</p>
<sec id="Sec16">
<title>Polygenic risk score prediction ability</title>
<p id="Par27">The main results are summarized in Table <xref ref-type="table" rid="Tab4">4</xref>. Variance analysis for the PRS and adjustment variables did not reveal any significant results. Basal Y-BOCS was a significant predictor of post Y-BOCS (<italic>Models 1</italic> and <italic>2</italic>; Table <xref ref-type="table" rid="Tab4">4</xref>, Supplemental Figure <xref ref-type="media" rid="MOESM1">S1</xref>), even when including the adjustment variables. Among these latter, only age was a significant predictor of post-treatment Y-BOCS (<italic>Model 3</italic>, Table <xref ref-type="table" rid="Tab4">4</xref>). However, age did not maintain its predictive power when the rest of the adjustment variables were included in the model (<italic>P</italic> = .11). The PRS was not a predictor of post Y-BOCS in any of these models.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Predictors for treatment response</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="3"><italic>Model 1</italic>. Post Y-BOCS regressed on <sub>Basal Y-BOCS</sub></th><th colspan="3"><italic>Model 2</italic>. Post Y-BOCS regressed on <sub>Basal Y-BOCS and PRS</sub></th><th colspan="3"><italic>Model 3</italic>. Post Y-BOCS regressed on <sub>Basal Y-BOCS, PRS and Age.</sub></th></tr><tr><th></th><th>
<sub><italic>B</italic></sub>
</th><th>
<sub>CI</sub>
</th><th>
<sub><italic>p</italic></sub>
</th><th>
<sub><italic>B</italic></sub>
</th><th>
<sub>CI</sub>
</th><th>
<sub><italic>p</italic></sub>
</th><th>
<sub><italic>B</italic></sub>
</th><th>
<sub>CI</sub>
</th><th>
<sub><italic>p</italic></sub>
</th></tr></thead><tbody><tr><td>
<italic>(Intercept)</italic>
</td><td>−2.04E-16</td><td>−0.13 to 0.13</td><td>1.000</td><td>0.01</td><td>−0.13 to 0.13</td><td>1.000</td><td>−3.83E-17</td><td>−0.13 to 0.13</td><td>1.000</td></tr><tr><td>
<italic>Basal Y- BOCS</italic>
</td><td>0.74</td><td>0.61 to 0.87</td><td>&lt;.001*</td><td>0.73</td><td>0.60 to 0.87</td><td>&lt;.001*</td><td>0.75</td><td>0.62 to 0.89</td><td>&lt;.001*</td></tr><tr><td>
<italic>PRS</italic>
</td><td></td><td></td><td></td><td>0.04</td><td>−0.10 to 0.18</td><td>.552</td><td>0.03</td><td>−0.11 to 0.16</td><td>.691</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.17</td><td>0.04 to 0.30</td><td>.009*</td></tr><tr><td>Observations</td><td></td><td>100</td><td></td><td></td><td>100</td><td></td><td></td><td>100</td><td></td></tr><tr><td><italic>R</italic><sup>2</sup>/adj. <italic>R</italic><sup>2</sup></td><td></td><td>.551/.547</td><td></td><td></td><td>.553/.544</td><td></td><td></td><td>.581/.568</td><td></td></tr><tr><td>AIC</td><td></td><td>208.677</td><td></td><td></td><td>210.324</td><td></td><td></td><td>205.691</td><td></td></tr></tbody></table><table-wrap-foot><p>The predictive abilities of Basal YBOCS, PRS and Age for Post YBOCS arepresented as Beta coefficients (β) from the regressions as well as with theproportion of variance explained by the models (<italic>R</italic><sup>2</sup>/Adj. <italic>R</italic><sup>2</sup>). The model fit isalso reported by the Akaike Information Criterion (AIC). <italic>Y-BOCS</italic> Yale-Brown obsessive-compulsive scale, <italic>PRS</italic> polygenic risk score. *<italic>p</italic> &lt; 0.05</p></table-wrap-foot></table-wrap></p>
<p id="Par28">Although the models barely differed from one another, <italic>Model 3</italic> showed the best fit (AIC = 205.691) and explained the highest proportion of variance (<italic>R</italic><sup>2</sup> = .581; adj. <italic>R</italic><sup>2</sup> = .568) (Table <xref ref-type="table" rid="Tab4">4</xref>). Considering that Model 3 seemed the best model and the PRS was not a predictor of post Y-BOCS, a new model was tested removing the PRS and maintaining age as an independent variable (Supplemental Table <xref ref-type="media" rid="MOESM1">S1</xref>). The AIC for this new model was lower than that for <italic>Model 3</italic> (Table <xref ref-type="table" rid="Tab4">4</xref>), presenting a better fit and explaining a relatively similar percentage of the variance (<italic>R</italic><sup>2</sup> = .575; adj. <italic>R</italic><sup>2</sup> = .566).</p>
<p id="Par29">In light of the above, the PRS was regressed on both Y-BOCS measures separately. The PRS seemed to significantly predict both post and basal Y-BOCS (Table <xref ref-type="table" rid="Tab5">5</xref>). The AIC for <italic>Model 4</italic> (AIC = 283.494) was higher than that for all previous models, thus showing a worse fit and explaining quite a low percentage of variance compared with the previous models (<italic>R</italic><sup>2</sup> = .052; adj. <italic>R</italic><sup>2</sup> = .043) (Table <xref ref-type="table" rid="Tab5">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>PRS predictive ability for YBOCS scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="3"><italic>Model 4</italic>. Post-YBOCS regressed on PRS</th><th colspan="3"><italic>Model 5</italic>. Basal Y-BOCS regressed on PRS</th></tr><tr><th></th><th>
<italic>β</italic>
</th><th>CI</th><th>
<italic>p</italic>
</th><th>
<italic>β</italic>
</th><th>CI</th><th>
<italic>p</italic>
</th></tr></thead><tbody><tr><td>(Intercept)</td><td>−4.37E-16</td><td>−0.19 to 0.19</td><td>1.000</td><td>−3.18E-16</td><td>−0.19 to 0.19</td><td>1.000</td></tr><tr><td>PRS</td><td>0.23</td><td>0.04 to 0.42</td><td>.020*</td><td>0.25</td><td>0.06 to 0.44</td><td>.009*</td></tr><tr><td>Observations</td><td>100</td><td>100</td><td></td><td></td><td></td><td></td></tr><tr><td><italic>R</italic><sup>2</sup> / adj. <italic>R</italic><sup>2</sup></td><td>.052 /.042</td><td>.064 /.055</td><td></td><td></td><td></td><td></td></tr><tr><td>AIC</td><td>283.494</td><td>282.118</td><td></td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>The predictive abilities of PRS for Post and Basal Y-BOCS are displayed as Beta values (β) from the regressions and the proportions of variance explained by the models (<italic>R</italic><sup>2</sup>/Adj. <italic>R</italic><sup>2)</sup>. The model fit is also reported by the Akaike Information Criterion (AIC)</p><p><italic>Y-BOCS</italic> Yale–Brown obsessive-compulsive scale, <italic>PRS</italic> polygenic risk score</p><p>*<italic>p</italic> &lt; .05</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec17">
<title>SLE at onset modulation ability</title>
<p id="Par30">Of the final target sample of 100 patients, 40 (40%) were categorized as SLE-preceded OCD and 60 (60%) as non-SLE-preceded OCD.</p>
<p id="Par31">ANOVA analyses of the PRS and SLEs at onset revealed significant differences in the PRS between those reporting a SLE at onset of the disorder and those who did not (<italic>t</italic> = 2.96; d<italic>f</italic> = 98; <italic>P</italic> = .004). In addition, significant associations were found between a SLE at onset and age at onset (<italic>t</italic> = 2.29; d<italic>f</italic> = 98; <italic>P</italic> = .024) and sex (<italic>χ</italic><sup><italic>2</italic></sup> = 4.93; <italic>df</italic> = 1; <italic>P</italic> = .039). These results are shown in Supplemental Tables <xref ref-type="media" rid="MOESM1">S2</xref> and <xref ref-type="media" rid="MOESM1">S3</xref>.</p>
<p id="Par32">According to the modulation analysis, a SLE at onset was not a predictor for post Y-BOCS when considering basal Y-BOCS and the PRS (<italic>B</italic> = -0.02; 95% CI, -0.29 to 0.26; <italic>P</italic> = .911), nor when any of the adjustment variables were included.</p>
</sec>
</sec>
</sec>
<sec id="Sec18" sec-type="discussion">
<title>Discussion</title>
<p id="Par33">This study was conducted to analyze if a PRS composed of OCD-risk genetic variants predicted treatment response in a sample of OCD patients, and whether this relation was modulated by SLEs at onset. According to the main regression analysis, the PRS did not predict treatment response, and basal Y-BOCS was the best predictor of post Y-BOCS in all cases. Only age, out of all the adjustment variables, showed a predictive capacity for treatment response, as those models that included it presented the best fit. An analysis of OCD severity indicated that the PRS was a predictor of both basal and post Y-BOCS. The results of a modulation analysis suggested that SLEs at onset did not play a significant role in treatment response when considering the PRS. Differences in SLE at onset prevalence were observed for the PRS, sex, and age at onset, whereby patients with a higher genetic risk, women, and those presenting a later age at onset were more likely to report a SLE at onset.</p>
<p id="Par34">With respect to the regression analysis, PRS was not a predictor for treatment response in our sample. Some evidences exist about the non-shared genetic bases of OCD risk and OCD treatment response<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>. In addition, although other studies have found an association between OCD treatment response and genes previously associated to OCD risk<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> (such as <italic>SLC1A1, SLC6A4</italic> or <italic>BDNF</italic><sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>), to our knowledge, only one genetic variant (rs3087879 in SLC1A1 gene) has been related to both OCD treatment response (a greater resistance) and OCD risk<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. We do not know to what extent this is due to different genetic bases of treatment response and OCD risk, since the variants studied in candidate gene association studies for OCD risk do not usually coincide with those studied for treatment response. Studies of other psychiatric disorders such as depression have also reported conflicting results regarding shared genetic bases for etiology and treatment response<sup><xref ref-type="bibr" rid="CR56">56</xref>–<xref ref-type="bibr" rid="CR62">62</xref></sup>. Furthermore, some of the variants found to be associated with both MDD risk and antidepressant response do it in the same direction (More MDD risk and worse treatment response) while others do it in the opposite (More MDD risk and better response)<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. Furthermore, PRS composed of risk genetic variants have also yielded inconsistent results as regards predicting SSRI treatment response in MDD patients<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>.</p>
<p id="Par35">It is also important to note the role that pharmacokinetic variants apparently play in treatment response<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. These are not specifically considered in PRS methodology since PRS composition is normally derived from GWAS performed in relation to phenotype rather than treatment response. In this regard, it might be interesting to analyze the predictive power of a PRS composed of response-associated rather than risk-associated variants, since these may be not the same. Further analyses of shared and non-shared genetic bases for OCD risk and treatment response will be necessary to enable the design of personalized pharmacological guidelines for OCD in the future.</p>
<p id="Par36">Our results regarding PRS associations with basal and post Y-BOCS were as expected, since a wide variety of genetic variants have been associated with a higher risk of OCD. Some of these variants are related to general nervous system structure and function (<italic>DISP1, SLC1A1, SLEC6A3, DRD3, 5HT3, BDNF</italic>:<sup><xref ref-type="bibr" rid="CR14">14</xref>-<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup>), neurodevelopment (<italic>NGFR</italic> and <italic>CDH9</italic>:<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>), neuroendocrinology (<italic>NR3A1</italic>:<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>), and mitochondrial functioning-related oxidative stress (<italic>MnSOD</italic> and <italic>UCP-2</italic> genes:<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>). Hence, it was expected that a PRS that combines numerous risk variants would predict OCD severity in a sample of patients. Similarly, a PRS composed of risk genetic variants for schizophrenia has emerged as a good predictor of OCD<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. The associations found between the PRS and both basal and post Y-BOCS seem to suggest that the PRS has the capacity to predict disorder severity independently of pharmacological intervention.</p>
<p id="Par37">It is important to note that given the predictive capacity of PRS for basal Y-BOCS, including both of them as predictors of post Y-BOCS is statistically redundant. However, including the PRS reduces the model’s statistical strength; thus, <italic>Model 2</italic> (Table <xref ref-type="table" rid="Tab4">4</xref>) presented a worse fit (AIC = 210.324) than the model that did not include the PRS (<italic>Model</italic> 1, Table <xref ref-type="table" rid="Tab4">4</xref>; AIC = 208.677). Hence, despite the collinearity of both the PRS and basal Y-BOCS, since including the PRS makes the model statistically weaker, <italic>Model 1</italic> is a better predictive model than <italic>Model 2</italic>.</p>
<p id="Par38">Our findings regarding the predictive power of age for treatment response agree with previous results associating a greater age at treatment with a worse response to SSRIs<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. In addition, the models including age as a predictor (<italic>Model 3</italic>, Table <xref ref-type="table" rid="Tab4">4</xref>; Table <xref ref-type="media" rid="MOESM1">S1</xref>) showed the best fit (AIC: 205.691; AIC: 203.849). This suggests that age might be an important factor in predicting treatment response in OCD.</p>
<p id="Par39">A worse response in older OCD patients could indicating a negative correlation between age and neuroplasticity, since it is well known that therapeutic effects of SRI are mediated by neuroplasticity mechanisms and that this decays with age<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup>. Then, SRI-induced neuroplasticity might not be as optimal in older patients when compared to younger ones. Further research should be developed to clarify this.</p>
<p id="Par40">As opposed to our results, other studies found response to coadjuvant risperidone in SRI-treated OCD patients to present a positive correlation with age<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. This might point out to the specificity of our findings for SRI monotherapy. Future research is required to confirm the predictive capacity of age for treatment response, since it could be an important predictor to account for in OCD-treatment.</p>
<p id="Par41">Analyses of the modulatory role of SLEs at onset showed that these were non-predictors for treatment response when included in the model. However, <italic>t</italic> test analyses revealed differences in the PRS between those reporting and not reporting a SLE at onset. One explanation for this apparent association might be that patients presenting a higher genetic risk for OCD could be more prone to developing the disorder when a SLE occurs. Thus, by itself, a SLE at onset may be insufficient to trigger OCD, but could play a role when other risk factors, such as genetic risk, already exist. Nonetheless, most authors have interpreted SLEs at onset as a reflection of environmentally-explained OCD<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Furthermore, compared to SLE-preceded patients, patients not reporting a SLE at onset tend to present a higher frequency of certain clinical characteristics, such as early age at onset or a family history of OCD<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>, which have been attributed to genetic factors<sup><xref ref-type="bibr" rid="CR71">71</xref>–<xref ref-type="bibr" rid="CR73">73</xref></sup>. These genetic factors might include rare variants with a larger effect than the common variants considered in the PRS, and therefore would not have been captured by our model. Further research is required to clarify the extent to which a SLE at onset can by itself trigger OCD, and to elucidate the real role that SLEs at onset may play in OCD etiology. Furthermore, although pathogenesis and treatment response in OCD are now relatively well established<sup><xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup>, the respective influence of environmental and genetic factors in triggering OCD remains unclear.</p>
<p id="Par42">It would also be interesting to analyze the modulatory role of other kinds of environmental factors that have consistently been shown to influence the development of OCD, such as lifetime<sup><xref ref-type="bibr" rid="CR76">76</xref></sup> or childhood<sup><xref ref-type="bibr" rid="CR77">77</xref>–<xref ref-type="bibr" rid="CR79">79</xref></sup> trauma. These environmental factors have also been shown to modify the influence exerted by genetic risk on OCD<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. Our results suggest that patients presenting a more neutral genomic profile could have an environmentally-explained OCD, in which other environmental factors not yet analyzed might be involved in development of the disorder.</p>
<p id="Par43">Our results concerning SLE associations with age at onset are in agreement with those reported in previous studies, in which non-SLE-preceded patients presented an earlier age of onset<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR80">80</xref></sup>. In addition, other studies have also found a higher rate of women reporting a SLE at onset<sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup>. This outcome agrees with the literature suggesting that women are more vulnerable to trauma experiences than men<sup><xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR83">83</xref></sup>.</p>
<p id="Par44">This study presented some limitations. For example, the size of the discovery (<italic>n</italic> = 370 cases; 443 controls) and target sample (<italic>n</italic> = 100) was probably insufficient in terms of statistical strength to enable identification of possible associations<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>. In addition, the target sample presented a somewhat low variability, since it consisted of patients already treated with at least one SSRI. We don’t know if results would have been different in naïve patients without a history of resistance to pharmacological treatment. In the analysis of SLE modulation, the dichotomic nature of our environmental variable might have hindered identification of significant associations. Inclusion of an environmental factor that could be treated as a quantitative variable would enable a richer analysis and facilitate identification of a possible modulatory role.</p>
<p id="Par45">This is the first study to explore the predictive power of an OCD-risk PRS for treatment response in OCD patients. Our goal was to shed light on the role that polygenic risk may play in treatment response in OCD probands, and the influence of a SLE at onset. Despite the reduced sample size and our negative results on PRS predictive value, some important findings arise from our study. First, the confirmation of age as influencing treatment response should state the importance of early OCD detection and treatment as essential. Secondly, we think that the study of the genetic predictors of SRI response should be expanded to other variants more than those implicated in the risk for affective and anxiety disorders, such as those involved in processes as neuroplasticity or drug-metabolism, while assuming the transdiagnostic aspect of SRI response. Understanding the factors that influence treatment response will enable the development of more individualized treatments that yield a better response and reduce secondary effects and the dropout rate. Further research will be necessary to elucidate the genetic and environmental bases of treatment response in OCD.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec19">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41398_2019_410_MOESM1_ESM.docx"><caption><p>Supplementary tables</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41398_2019_410_MOESM2_ESM.pdf"><caption><p>Supplementary Figure (Figure S1)</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p><bold>Publisher’s note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<sec>
<title>
<bold>Supplementary Information</bold>
</title>
<p><bold>Supplementary Information</bold> accompanies this paper at (10.1038/s41398-019-0410-0).</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This study was supported in part by the Carlos III Health Institute (PI13/01958, PI13/00918, PI14/00413 and PI16/00950); FEDER funds (‘A way to build Europe’) and by the Agency of University and Research Funding Management of the Catalan Government (2014SGR1672). We also acknowledge support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2017-2021’, SEV-2016-0571 and of the Spanish MINECO SAF2013-49108-R Plan Estatal. M.A. was supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia. Grant co-funded by the European Social Fund (ESF) “ESF, Investing in your future” (2017 FI_B 00327). E.R. was supported by a Juan Rodés contract (JR14/00038). We thank all the study participants from the Department of Psychiatry of Hospital Universitari de Bellvitge who collaborated to obtain the sample of this study, and Cristian Tebe Cordomi and Natalia Pallares Fontanet, from the Statistical Assessment Service (Institut d’Investigació Biomèdica de Bellvitge)</p>
</ack>
<notes notes-type="COI-statement">
<sec id="FPar1">
<title>Conflict of interest</title>
<p>The authors declare that they have no conflict of interest.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobes</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quality of life and disability in patients with obsessive-compulsive disorder</article-title>
<source/>Eur. Psychiatry
          <year>2001</year>
<volume>16</volume>
<fpage>239</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="pmid">11418275</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storch</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Abramowitz</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Keeley</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Correlates and mediators of functional disability in obsessive-compulsive disorder</article-title>
<source/>Depress Anxiety
          <year>2009</year>
<volume>26</volume>
<fpage>806</fpage>
<lpage>813</lpage>
<pub-id pub-id-type="pmid">19170106</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruscio</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication</article-title>
<source/>Mol. Psychiatry
          <year>2010</year>
<volume>15</volume>
<fpage>53</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">18725912</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fineberg</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Gale</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Evidence-based pharmacotherapy of obsessive–compulsive disorder</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2005</year>
<volume>8</volume>
<fpage>107</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="pmid">15450126</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tükel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bozkurt</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Polat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Genç</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Atli</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder</article-title>
<source/>Psychiatry Clin. Neurosci.
          <year>2006</year>
<volume>60</volume>
<fpage>404</fpage>
<lpage>409</lpage>
<pub-id pub-id-type="pmid">16884439</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheaton</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Rosenfield</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Foa</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>HB</given-names>
</name>
</person-group>
<article-title>Augmenting serotonin reuptake inhibitors in obsessive–compulsive disorder: What moderates improvement?</article-title>
<source/>J. Consult. Clin. Psychol.
          <year>2015</year>
<volume>83</volume>
<fpage>926</fpage>
<lpage>937</lpage>
<pub-id pub-id-type="pmid">26009783</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dold</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aigner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lanzenberger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Evaluation of the efficacy of antipsychotic drugs in sri-resistant obsessive-compulsive disorder</article-title>
<source/>Eur. Psychiatry
          <year>2015</year>
<volume>30</volume>
<fpage>795</fpage>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abudy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Juven-Wetzler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zohar</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Pharmacological management of treatment-resistant obsessive-compulsive disorder</article-title>
<source/>Cns. Drugs
          <year>2011</year>
<volume>25</volume>
<fpage>585</fpage>
<lpage>596</lpage>
<pub-id pub-id-type="pmid">21699270</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zai</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brandl</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of antidepressant treatment in obsessive–compulsive disorder: an update and implications for clinicians</article-title>
<source/>Pharmacogenomics
          <year>2014</year>
<volume>15</volume>
<fpage>1147</fpage>
<lpage>1157</lpage>
<pub-id pub-id-type="pmid">25084207</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corregiari</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bernik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cordeiro</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Vallada</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder</article-title>
<source/>Clinics
          <year>2012</year>
<volume>67</volume>
<fpage>335</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="pmid">22522758</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vulink</surname>
<given-names>NCC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder</article-title>
<source/>Int J. Psychiatry Clin. Pract.
          <year>2012</year>
<volume>16</volume>
<fpage>277</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="pmid">22414277</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Real</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive-compulsive disorder</article-title>
<source/>Pharm. J.
          <year>2013</year>
<volume>13</volume>
<fpage>470</fpage>
<lpage>475</lpage>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Real</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder</article-title>
<source/>Biol. Psychiatry
          <year>2009</year>
<volume>66</volume>
<fpage>674</fpage>
<lpage>680</lpage>
<pub-id pub-id-type="pmid">19589503</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dhilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Charalambous</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gogos</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Karayiorgou</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Sequence variants of the brain-derived neurotrophic factor (bdnf) gene are strongly associated with obsessive-compulsive disorder</article-title>
<source/>Am. J. Hum. Genet.
          <year>2003</year>
<volume>73</volume>
<fpage>370</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="pmid">12836135</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alonso</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Extensive genotyping of the BDNF and NTRK2 genes define protective haplotypes against obsessive-compulsive disorder</article-title>
<source/>Biol. Psychiatry
          <year>2008</year>
<volume>63</volume>
<fpage>619</fpage>
<lpage>628</lpage>
<pub-id pub-id-type="pmid">17884018</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tükel</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of the brain-derived neurotrophic factor SNP rs2883187 in the phenotypic expression of obsessive-compulsive disorder</article-title>
<source/>J. Clin. Neurosci.
          <year>2014</year>
<volume>21</volume>
<fpage>790</fpage>
<lpage>793</lpage>
<pub-id pub-id-type="pmid">24291483</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gassó</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder</article-title>
<source/>J. Affect Disord.
          <year>2015</year>
<volume>186</volume>
<fpage>284</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="pmid">26254621</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGregor</surname>
<given-names>NW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modification of the association between early adversity and obsessive-compulsive disorder by polymorphisms in the MAOA, MAOB and COMT genes</article-title>
<source/>Psychiatry Res.
          <year>2016</year>
<volume>246</volume>
<fpage>527</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="pmid">27821364</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomes</surname>
<given-names>CKF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association analysis of SLC6A4 and HTR2A genes with obsessive-compulsive disorder: influence of the STin2 polymorphism</article-title>
<source/>Compr. Psychiatry
          <year>2018</year>
<volume>82</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">29331882</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The AmpliChip ® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism</article-title>
<source/>Genet. Test. Mol. Biomark.
          <year>2012</year>
<volume>16</volume>
<fpage>897</fpage>
<lpage>903</lpage>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandl</surname>
<given-names>EJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder</article-title>
<source/>Pharm. J.
          <year>2014</year>
<volume>14</volume>
<fpage>176</fpage>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-genome association analysis of treatment response in obsessive-compulsive disorder</article-title>
<source/>Mol. Psychiatry
          <year>2016</year>
<volume>21</volume>
<fpage>270</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">25824302</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common polygenic variation contributes to risk of schizophrenia and bipolar disorder</article-title>
<source/>Nature
          <year>2009</year>
<volume>460</volume>
<fpage>748</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="pmid">19571811</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wray</surname>
<given-names>NR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Research review: Polygenic methods and their application to psychiatric traits</article-title>
<source/>J. Child Psychol. Psychiatry Allied Discip.
          <year>2014</year>
<volume>55</volume>
<fpage>1068</fpage>
<lpage>1087</lpage>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hettige</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Khalid</surname>
<given-names>S</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Polygenic risk score prediction of antipsychotic dosage in schizophrenia</article-title>
<source/>Schizophr. Res.
          <year>2016</year>
<volume>170</volume>
<fpage>265</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="pmid">26778674</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Gendep Investigators, Mars Investigators, Star* D Investigators.</collab>
</person-group>
<article-title>Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies</article-title>
<source/>Am. J. Psyquiatry
          <year>2013</year>
<volume>170</volume>
<fpage>207</fpage>
<lpage>217</lpage>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>García-González</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenetics of antidepressant response: a polygenic approach</article-title>
<source/>Prog. Neuro-Psychopharmacol. Biol. Psychiatry
          <year>2017</year>
<volume>75</volume>
<fpage>128</fpage>
<lpage>134</lpage>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douglas</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>The effect of childhood trauma on pharmacological treatment response in depressed inpatients</article-title>
<source/>Psychiatry Res.
          <year>2012</year>
<volume>200</volume>
<fpage>1058</fpage>
<lpage>1061</lpage>
<pub-id pub-id-type="pmid">22770764</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harkness</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Michael Bagby</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Childhood maltreatment and differential treatment response and recurrence in adult major depressive disorder</article-title>
<source/>J. Consult. Clin. Psychol.
          <year>2012</year>
<volume>80</volume>
<fpage>342</fpage>
<pub-id pub-id-type="pmid">22428942</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nanni</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Uher</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Danese</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis</article-title>
<source/>Am. J. Psychiatry
          <year>2012</year>
<volume>169</volume>
<fpage>141</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="pmid">22420036</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quilty</surname>
<given-names>LC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Childhood abuse history in depression predicts better response to antidepressants with higher serotonin transporter affinity: a pilot investigation</article-title>
<source/>Neuropsychobiology
          <year>2017</year>
<volume>74</volume>
<fpage>78</fpage>
<lpage>83</lpage>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruce</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Heimberg</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Blanco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schneier</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Liebowitz</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Childhood maltreatment and social anxiety disorder: Implications for symptom severity and response to pharmacotherapy</article-title>
<source/>Depress Anxiety
          <year>2012</year>
<volume>29</volume>
<fpage>132</fpage>
<lpage>139</lpage>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gershuny</surname>
<given-names>BS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Trauma and posttraumatic stress disorder in treatment-resistant obsessive-compulsive disorder</article-title>
<source/>Depress Anxiety
          <year>2008</year>
<volume>25</volume>
<fpage>69</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">17318836</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shavitt</surname>
<given-names>RG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder</article-title>
<source/>Eur. Arch. Psychiatry Clin. Neurosci.
          <year>2010</year>
<volume>260</volume>
<fpage>91</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">20077119</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keers</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project</article-title>
<source/>Pharm. J.
          <year>2011</year>
<volume>11</volume>
<fpage>138</fpage>
<lpage>145</lpage>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandelli</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment</article-title>
<source/>Hum. Psychopharmacol.
          <year>2014</year>
<volume>29</volume>
<fpage>388</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="pmid">25163442</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response</article-title>
<source/>J. Affect Disord.
          <year>2011</year>
<volume>133</volume>
<fpage>165</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="pmid">21680027</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<mixed-citation publication-type="other">American Psychiatric Association. <italic>Diagnostic and Statistical Manual of Mental Disorders</italic> 4th edn, (American Psychiatric Press: Washington, DC, 1994).</mixed-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<mixed-citation publication-type="other">First, M. B., Spitzer, R. L., Gibbon, M. &amp; Williams, J. B. W. <italic>Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV)</italic> (American Psychiatric Press: Washington, DC, 1997).</mixed-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>WK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability</article-title>
<source/>Arch. Gen. Psychiatry
          <year>1989</year>
<volume>46</volume>
<fpage>1006</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="pmid">2684084</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosario-Campos</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Dimensional Yale–Brown Obsessive–Compulsive Scale (DY-BOCS): an instrument for assessing obsessive–compulsive symptom dimensions</article-title>
<source/>Mol. Psychiatry
          <year>2006</year>
<volume>11</volume>
<fpage>495</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="pmid">16432526</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paykel</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Prusoff</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Uhlenhuth</surname>
<given-names>EH</given-names>
</name>
</person-group>
<article-title>Scaling of life events</article-title>
<source/>Arch. Gen. Psychiatry
          <year>1971</year>
<volume>25</volume>
<fpage>340</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="pmid">5116988</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costas</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia</article-title>
<source/>Transl. Psychiatry
          <year>2016</year>
<volume>6</volume>
<fpage>e768</fpage>
<pub-id pub-id-type="pmid">27023174</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gusev</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases</article-title>
<source/>Am. J. Hum. Genet.
          <year>2014</year>
<volume>95</volume>
<fpage>535</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="pmid">25439723</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finucane</surname>
<given-names>HK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Partitioning heritability by functional annotation using genome-wide association summary statistics</article-title>
<source/>Nat. Genet.
          <year>2015</year>
<volume>47</volume>
<fpage>1228</fpage>
<lpage>1235</lpage>
<pub-id pub-id-type="pmid">26414678</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Speed</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Nejentsev</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Balding</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Reevaluation of SNP heritability in complex human traits</article-title>
<source/>Nat. Genet.
          <year>2017</year>
<volume>49</volume>
<fpage>986</fpage>
<lpage>992</lpage>
<pub-id pub-id-type="pmid">28530675</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PLINKS: a tool set for whole-genome association and population-based linkage analyses</article-title>
<source/>Am. J. Hum. Genet.
          <year>2007</year>
<volume>81</volume>
<fpage>559</fpage>
<lpage>575</lpage>
<pub-id pub-id-type="pmid">17701901</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storch</surname>
<given-names>EA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical predictors of early fluoxetine treatment response in obsessive–compulsive disorder</article-title>
<source/>Depress Anxiety
          <year>2006</year>
<volume>23</volume>
<fpage>429</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="pmid">16841343</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albert</surname>
<given-names>U</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Admixture analysis of age at symptom onset and age at disorder onset in a large sample of patients with obsessive-compulsive disorder</article-title>
<source/>J. Affect Disord.
          <year>2015</year>
<volume>187</volume>
<fpage>188</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">26339929</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldberg</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Predictive value of familiality, stressful life events and gender on the course of obsessive-compulsive disorder</article-title>
<source/>J. Affect Disord.
          <year>2015</year>
<volume>185</volume>
<fpage>129</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="pmid">26172984</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mas</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrating genetic, neuropsychological and neuroimaging data to model early-onset obsessive compulsive disorder severity</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<fpage>e0153846</fpage>
<pub-id pub-id-type="pmid">27093171</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Molecular genetics of obsessive-compulsive disorder: A comprehensive meta-analysis of genetic association studies</article-title>
<source/>Mol. Psychiatry
          <year>2013</year>
<volume>18</volume>
<fpage>799</fpage>
<lpage>805</lpage>
<pub-id pub-id-type="pmid">22665263</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>SE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genomewide association study of obsessive-compulsive disorder</article-title>
<source/>Mol. Psychiatry
          <year>2013</year>
<volume>18</volume>
<fpage>788</fpage>
<lpage>798</lpage>
<pub-id pub-id-type="pmid">22889921</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthiesen</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS</article-title>
<source/>Mol. Psychiatry
          <year>2015</year>
<volume>20</volume>
<fpage>337</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="pmid">24821223</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukla</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenetic association between glutamatergic genes and SRI treatment response in obsessive compulsive disorder</article-title>
<source/>Eur. Psychiatry
          <year>2017</year>
<volume>41</volume>
<fpage>S111</fpage>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression</article-title>
<source/>Psychopharmacol. (Berl.)
          <year>2014</year>
<volume>231</volume>
<fpage>685</fpage>
<lpage>693</lpage>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zill</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence for an association between a G-protein β3-gene variant with depression and response to antidepressant treatment</article-title>
<source/>Neuroreport
          <year>2000</year>
<volume>11</volume>
<fpage>1893</fpage>
<lpage>1897</lpage>
<pub-id pub-id-type="pmid">10884039</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bhagwagar</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Antidepressant response and the serotonin transporter gene-linked polymorphic region</article-title>
<source/>Biol. Psychiatry
          <year>2010</year>
<volume>68</volume>
<fpage>536</fpage>
<lpage>543</lpage>
<pub-id pub-id-type="pmid">20615496</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kishi</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder</article-title>
<source/>J. Affect Disord.
          <year>2012</year>
<volume>142</volume>
<fpage>315</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="pmid">22770721</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitjans</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>227</volume>
<fpage>509</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="pmid">23407780</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ventura-Juncá</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study</article-title>
<source/>BMC Psychiatry
          <year>2014</year>
<volume>14</volume>
<fpage>1</fpage>
<lpage>13</lpage>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Sousa</surname>
<given-names>RT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic studies on the tripartite glutamate synapse in the pathophysiology and therapeutics of mood disorders</article-title>
<source/>Neuropsychopharmacology
          <year>2017</year>
<volume>42</volume>
<fpage>787</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="pmid">27510426</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tansey</surname>
<given-names>KE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis</article-title>
<source/>PLoS. Med.
          <year>2012</year>
<volume>9</volume>
<fpage>e1001326</fpage>
<pub-id pub-id-type="pmid">23091423</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common variants of HTR3 genes are associated with obsessive-compulsive disorder and its phenotypic expression</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">28442746</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alonso</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Variants in estrogen receptor alpha gene are associated with phenotypical expression of obsessive-compulsive disorder</article-title>
<source/>Psychoneuroendocrinology
          <year>2011</year>
<volume>36</volume>
<fpage>473</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">20850223</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orhan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kucukali</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Cakir</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Seker</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetic variants in nuclear-encoded mitochondrial proteins are associated with oxidative stress in obsessive compulsive disorders</article-title>
<source/>J. Psychiatr. Res.
          <year>2012</year>
<volume>46</volume>
<fpage>212</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="pmid">22070905</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<mixed-citation publication-type="other">Umemori, J., Winkel, F., Didio, G., Pou, M. L. &amp; Castrén, E. iPlasticity: induced juvenile-like plasticity in the adult brain as a mechanism of antidepressants. <italic>Psychiatry Clin. Neurosci.</italic>10.1111/pcn.12683 (2018).</mixed-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<mixed-citation publication-type="other">Eavri, R. <italic>et</italic><italic>al</italic>. Interneuron simplification and loss of structural plasticity as markers of aging-related functional decline. <italic>J. Neurosci</italic>. <bold>38</bold>, 8421–8432 (2018).</mixed-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheaton</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Rosenfield</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Foa</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>HB</given-names>
</name>
</person-group>
<article-title>Augmenting serotonin reuptake inhibitors in obsessive–compulsive disorder: What moderates improvement?</article-title>
<source/>J. Consult. Clin. Psychol.
          <year>2015</year>
<volume>83</volume>
<fpage>926</fpage>
<pub-id pub-id-type="pmid">26009783</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Real</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Stressful life events at onset of obsessive-compulsive disorder are associated with a distinct clinical pattern</article-title>
<source/>Depress Anxiety
          <year>2011</year>
<volume>28</volume>
<fpage>367</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="pmid">21308889</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauls</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Alsobrook</surname>
<given-names>IIJP</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leckman</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>A family study of obsessive-compulsive disorder</article-title>
<source/>Am. J. Psychiatry
          <year>1995</year>
<volume>152</volume>
<fpage>76</fpage>
<pub-id pub-id-type="pmid">7802125</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickel</surname>
<given-names>DE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2006</year>
<volume>63</volume>
<fpage>778</fpage>
<lpage>785</lpage>
<pub-id pub-id-type="pmid">16818867</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samuels</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comprehensive family‐based association study of the glutamate transporter gene SLC1A1 in obsessive‐compulsive disorder</article-title>
<source/>Am. J. Med. Genet.
          <year>2011</year>
<volume>156</volume>
<fpage>472</fpage>
<lpage>477</lpage>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bloch</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Landeros-Weisenberger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rosario</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Pittenger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leckman</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Meta-analysis of the symptom structure of obsessive-compulsive disorder</article-title>
<source/>Am. J. Psychiatry
          <year>2008</year>
<volume>165</volume>
<fpage>1532</fpage>
<lpage>1542</lpage>
<pub-id pub-id-type="pmid">18923068</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauls</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Abramovitch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2014</year>
<volume>15</volume>
<fpage>410</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="pmid">24840803</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cromer</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>An investigation of traumatic life events and obsessive-compulsive disorder</article-title>
<source/>Behav. Res. Ther.
          <year>2007</year>
<volume>45</volume>
<fpage>1683</fpage>
<lpage>1691</lpage>
<pub-id pub-id-type="pmid">17067548</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carpenter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Childhood trauma in obsessive compulsive disorder: The roles of alexithymia and attachment</article-title>
<source/>Psychol. Psychother. Theory, Res Pract.
          <year>2011</year>
<volume>84</volume>
<fpage>367</fpage>
<lpage>388</lpage>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kıvılcım</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Erensoy</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tonguç</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Sarıdogan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ebru</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The comorbidity of traumatic life events in childhood age with adult obsessive-compulsive disorder</article-title>
<source/>Eur. Psychiatry
          <year>2016</year>
<volume>33</volume>
<fpage>S497</fpage>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemmings</surname>
<given-names>SMJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>BDNF Val66Met modifies the risk of childhood trauma on obsessive-compulsive disorder</article-title>
<source/>J. Psychiatr. Res.
          <year>2013</year>
<volume>47</volume>
<fpage>1857</fpage>
<lpage>1863</lpage>
<pub-id pub-id-type="pmid">24050777</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Real</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain structural correlates of obsessive–compulsive disorder with and without preceding stressful life events</article-title>
<source/>World J. Biol. Psychiatry
          <year>2016</year>
<volume>17</volume>
<fpage>366</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="pmid">26784523</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosso</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Asinari</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Bogetto</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Maina</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Stressful life events and obsessive–compulsive disorder: clinical features and symptom dimensions</article-title>
<source/>Psychiatry Res.
          <year>2012</year>
<volume>197</volume>
<fpage>259</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="pmid">22370150</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irish</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gender differences in PTSD symptoms: An exploration of peritraumatic mechanisms</article-title>
<source/>J. Anxiety Disord.
          <year>2011</year>
<volume>25</volume>
<fpage>209</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="pmid">20956066</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaske</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Newsome</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Interaction of serotonin transporter linked polymorphic region and childhood neglect on criminal behavior and substance use for males and females</article-title>
<source/>Dev. Psychopathol.
          <year>2012</year>
<volume>24</volume>
<fpage>181</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="pmid">22293003</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dudbridge</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Power and predictive accuracy of polygenic risk scores</article-title>
<source/>PLoS. Genet.
          <year>2013</year>
<volume>9</volume>
<fpage>e1003348</fpage>
<pub-id pub-id-type="pmid">23555274</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>